Elisha Woodfield has lived with a rare, debilitating condition that has left her covered in ulcers and lesions since first ...

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Behçet's syndrome is a form of autoimmune vasculitis marked by widespread and sometimes life-threatening cardiovascular complications, as well as skin, nervous system, and gastrointestinal lesions.

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...

Behçet’s disease is a chronic, relapsing multisystem vasculitis with a striking geographical gradient, being most common along the historic Silk Road but reported worldwide. Its aetiology is ...

Soligenix shares surged more than 50% in early trading Monday after the late-stage biopharmaceutical company won U.S. Food and Drug Administration orphan-drug designation for the active ingredient in ...